- Home
- TXO vs SLS Comparison
TXO vs SLS Comparison
Compare TXO & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TXO | SLS |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.6M | 706.7M |
| IPO Year | 2022 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TXO | SLS |
|---|---|---|
| Price | $11.46 | $5.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $20.50 | $10.00 |
| AVG Volume (30 Days) | 207.1K | ★ 5.5M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 14.47% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $401,012,000.00 | N/A |
| Revenue This Year | $17.21 | N/A |
| Revenue Next Year | N/A | $67.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.80 | N/A |
| 52 Week Low | $10.12 | $1.27 |
| 52 Week High | $17.90 | $6.14 |
Technical Indicators
Market Signals| Indicator | TXO | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 30.50 | 56.44 |
| Support Level | N/A | $4.70 |
| Resistance Level | $13.05 | $5.18 |
| Average True Range (ATR) | 0.44 | 0.28 |
| MACD | -0.13 | 0.05 |
| Stochastic Oscillator | 11.28 | 97.15 |
Price Performance
Historical ComparisonAbout TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America. Its operations focus on enhancing the development and operation of producing properties through its concentration on efficiency and optimizing exploitation of current wells.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.